Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669002 · ClinicalTrials.gov registry record · Phase 2
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
A Phase 2 study, sponsored by Ellipses Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04669002: Completed Phase 2 study, sponsored by Ellipses Pharma.
NCT04669002 is a Phase 2 study that has completed, run by Ellipses Pharma. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669002, a Phase 2 study, has completed, sponsored by Ellipses Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve therapeutic responses in the recurrent ovarian cancer disease setting. EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and as a result create preferential accumulation of EP0057, and therefore of the payload Camptothecin, to translate into maximum tumour cell killing.
Primary Outcome
Overall Response Rate as measured using RECIST1.1
Interventions
- DRUG EP0057
- DRUG Olaparib tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
What the finished NCT04669002 record still lists
NCT04669002 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which EP0057 is the first listed.
NCT04669002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04669002 about?
NCT04669002 is a clinical study titled "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer". EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination...
What is the current status of trial NCT04669002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-12-14. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04669002?
The interventions under investigation include: EP0057 (DRUG), Olaparib tablets (DRUG).
Who is sponsoring clinical trial NCT04669002?
This trial is sponsored by Ellipses Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04669002's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI